摘要
H型高血压是伴有血浆同型半胱氨酸升高的原发性高血压,约占我国成年人高血压的75%,与脑卒中及其他心血管疾病密切相关,可能是一个重要的、独立的危险因素。治疗H型高血压时应同时降低血压及血浆同型半胱氨酸的水平,目前的循证医学证据支持依那普利叶酸片在治疗H型高血压中的运用,但仍需大规模的前瞻性研究证实其有效性及安全性。
H type hypertension is described as primary hypertension with elevated plasma homocysteine level,accounts for about 75 percent in Chinese hypertensive patients.H type hypertension is closely associated with cardiovascular and cerebrovascular diseases,may be an independent risk factor.Lowering blood and homocysteine level should be considered.In addition,current evidence-based studies have confirmed the effect of enalapril/folic acid for H type hypertension.However,the larger,prospective,multicentre,and randomized controlled trials still need to assess the effect and safety of enalapril/folic acid for H type hypertension.
出处
《心血管病学进展》
CAS
2012年第2期250-252,共3页
Advances in Cardiovascular Diseases
关键词
H型高血压
同型半胱氨酸
高血压
叶酸
H type hypertension
homocysteine
hypertension
folic acid
